Live Breaking News & Updates on Of Eigr

Global Phase 3 D-LIVR study enrollment completion planned in 2021
Peginterferon Lambda for HDV
Global Phase 3 LIMT-2 study initiation planned in 2021
Zokinvy™ (lonafarnib) for Progeria and Processing-Deficient Progeroid Laminopathies
U.S. commercial launch in January 2021
EMA decision expected in 2H21
Lambda for COVID-19
Lancet Respiratory Medicine (Feld et al, 2021)
Considering strategic options to advance program
Avexitide for Post-Bariatric Hypoglycemia (PBH)
Positive Phase 2 PREVENT study published in
JCEM (Craig et al, 2021)
Corporate
Pro-forma cash, cash equivalents and investments of $176.2M, including $128.8M as of December 31, 2020 plus $47.4M from net PRV sale proceeds received in January 2021, expected to fund planned operations through Q4 2023
Fourth Quarter and Full Year 2020 Financial Results ....

Progeroid Laminopathies , David Cory , Drug Administration , Program Product Updates , Company Annual Report On Form , Prnewswire Eiger Biopharmaceuticals Inc , European Medicines Agency , Eiger Biopharmaceuticals Inc , Access Program , Hepatitis Delta Virus , Processing Deficient Progeroid , Lancet Respiratory Medicine , Post Bariatric Hypoglycemia , Full Year , Priority Review Voucher , Hutchinson Gilford Progeria Syndrome , Marketing Authorization Application , Managed Access Program , Quarterly Report , Annual Report , Consolidated Statements , Operations Financial , Eiger Biopharmaceuticals , Inc Stock Exchange , Press Release , Of Eigr ,